Intra-Cellular Therapies, Inc. logo

Intra-Cellular Therapies, Inc.

NASDAQ:ITCI

Overview | Financials
Company Name Intra-Cellular Therapies, Inc.
Symbol ITCI
Currency USD
Price 131.36
Market Cap 13,967,246,080
Dividend Yield 0%
52-week-range 63.3 - 131.37
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. Sharon Mates Ph.D.
Website https://www.intracellulartherapies.com

An error occurred while fetching data.

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in developing lumateperone, which

Related Stocks

Azenta, Inc. logo

Azenta, Inc.

AZTA

36.56 USD

Ionis Pharmaceuticals, Inc. logo

Ionis Pharmaceuticals, Inc.

IONS

32.9 USD

10x Genomics, Inc. logo

10x Genomics, Inc.

TXG

9.88 USD

Option Care Health, Inc. logo

Option Care Health, Inc.

OPCH

32.24 USD

HealthEquity, Inc. logo

HealthEquity, Inc.

HQY

93.97 USD

Integra LifeSciences Holdings Corporation logo

Integra LifeSciences Holdings Corporation

IART

22.27 USD

Exelixis, Inc. logo

Exelixis, Inc.

EXEL

36.8 USD

Omnicell, Inc. logo

Omnicell, Inc.

OMCL

32.28 USD

Financials

Numbers are in millions USD

Numbers are in millions USD